Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase I Trial

Christiane Querfeld, MD PhD, John Thompson, MD, Matthew H. Taylor, MD, Raju Pillai, MD, Lisa DS Johnson, PhD, Tina Catalano, MSc, Penka S. Petrova, PhD, Theresa Thompson, Robert A. Uger, PhD, Yaping Shou, MD PhD, Oleg E. Akilov, MD

Blood (2018) 132 (Supplement 1): 1653.

https://doi.org/10.1182/blood-2018-99-116915

Published: 2018

Journal Articles

A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 "Do Not Eat" Signal

Christiane Querfeld, MD PhD, John Thompson, MD, Matthew Taylor, Raju Pillai, MD, Lisa DS Johnson, PhD, Tina Catalano, MSc, Penka S. Petrova, PhD, Robert A. Uger, PhD, Meghan Irwin, BSc, EMBA, Eric L Sievers, MD, Oleg E. Akilov, MD

Blood (2017) 130 (Supplement 1): 4076.

https://doi.org/10.1182/blood.V130.Suppl_1.4076.4076

Published: 2017

Journal Articles

Mature Results of a Phase 1-2 Open-Label, Dose-Escalation Study of Intravenous SNS01-T in Patients (pts) with Relapsed or Refractory B-Cell Malignancies

David S. Siegel, MD PhD, Andrew McDonald, MBChB, Nicolas Novitzky, MD PhD, William Bensinger, Michael Craig, MD, Frits van Rhee, MD PhD, Martin Gutierrez, MD, Edward N. Libby, MD, John Thompson, Alice S Bexon, MD, Charles Barranco, Catherine A Taylor, Richard Dondero, Leslie J. Browne, PhD, Michael R. Kurman, MD, John A. Lust, MD PhD

Blood (2014) 124 (21): 4464.

https://doi.org/10.1182/blood.V124.21.4464.4464

Published: 2014

Journal Articles

Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of a Novel, First-in-Class Modulator of Eukaryotic Translation Initiation Factor 5A (eIF5A) in Patients (pts) with Relapsed or Refractory B-Cell Malignancies: Data from a Phase 1-2 Study

Alice S Bexon, MD, Michael Craig, MD, David S. Siegel, MD PhD, William Bensinger, Nicolas Novitzky, MD PhD, Andrew McDonald, MBChB, Martin Gutierrez, MD, Edward N. Libby, MD, Frits van Rhee, MD PhD, Jeremy Heidel, PhD, John Thompson, Charles Barranco, Catherine A Taylor, Kathleen A. Donovan, PhD, Laurie L. Moon-Tasson, BA, Leslie J. Browne, PhD, Michael R. Kurman, MD, John A. Lust, MD PhD, Richard Dondero

Blood (2014) 124 (21): 2121.

https://doi.org/10.1182/blood.V124.21.2121.2121

Published: 2014

Journal Articles

Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study To Evaluate The Safety and Tolerability Of Intravenous Infusion Of SNS01-T In Patients With Relapsed Or Refractory Multiple Myeloma, Mantle Cell Lymphoma, Or Diffuse Large B Cell Lymphoma

John A Lust, Charles Barranco, Saad Z Usmani, MD FACP, Frits van Rhee, MD, PhD, Mehdi Hamadani, MD, John Thompson, Catherine A Taylor, Richard Dondero, Leslie J. Browne, PhD, David Siegel, William I. Bensinger, MD

Blood (2013) 122 (21): 1950.

https://doi.org/10.1182/blood.V122.21.1950.1950

Published: 2013

Journal Articles

Sensitive and Specific Antibody Probes Directed Against The Erythropoietin Receptor – From Basic Studies To Clinical Implementation

Blood (2013) 122 (21): 2175.

https://doi.org/10.1182/blood.V122.21.2175.2175

Published: 2013

Journal Articles

Apixaban Reduces Hospitalization In Patients With Venous Thromboembolism: An Analysis Of The AMPLIFY-EXT Trial

Xianchen Liu, MD, PhD, John Thompson, PhD, Hemant Phatak, PhD, Jack Mardekian, PhD, Anthony R. Porcari, PhD, PharmD, Margot R. Johnson, MD, BSC

Blood (2013) 122 (21): 3638.

https://doi.org/10.1182/blood.V122.21.3638.3638

Published: 2013

Journal Articles

SNS01-T Exhibits Significant Anti-Tumoral Activity In Models Of Multiple Myeloma and Non-Hodgkins B Cell Lymphoma and Induces Cell Death In Malignant But Not Normal B Cells

Catherine A Taylor, Terence Tang, Sarah Francis, Zhongda Liu, Qifa Zheng, Richard Dondero, John Thompson

Blood (2013) 122 (21): 880.

https://doi.org/10.1182/blood.V122.21.880.880

Published: 2013

Journal Articles

Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma.

John A Lust, MD, PhD, Saad Z Usmani, MD FACP, Mehdi Hamadani, MD, Charles Barranco, Martha Q Lacy, MD, Angela Dispenzieri, MD, Morie A Gertz, David Dingli, M.D., Ph.D., Stephen Russell, MD, PhD, Francis K Buadi, M.D., Steven R Zeldenrust, MD, PhD, Suzanne R Hayman, MD, S. Vincent Rajkumar, MD, Shaji K. Kumar, MD, John Thompson, Catherine A Taylor, Richard Dondero

Blood (2012) 120 (21): 2973.

https://doi.org/10.1182/blood.V120.21.2973.2973

Published: 2012

Journal Articles

Combination Therapy with Novel Nanoparticle, SNS01-T, and Lenalidomide Triggers Synergistic Cytotoxicity in Vitro and in Vivo in Multiple Myeloma and Mantle Cell Lymphoma

Catherine A Taylor, Terence Tang, Zhongda Liu, Sarah Francis, Zheng Qifa, Richard Dondero, John Thompson

Blood (2012) 120 (21): 4223.

https://doi.org/10.1182/blood.V120.21.4223.4223

Published: 2012

Journal Articles

Pharmacodynamic, Biodistribution and Toxicology Results for SNS01-T, a Nanoparticle That Targets eIF5A for the Treatment of Multiple Myeloma

Richard Dondero, Saad Usmani, MD, FACP, Catherine A Taylor, Zhongda Liu, Tang Terence, John Thompson

Blood (2011) 118 (21): 2051.

https://doi.org/10.1182/blood.V118.21.2051.2051

Published: 2011

Journal Articles

HLA mismatching within or outside of cross-reactive groups (CREGs) is associated with similar outcomes after unrelated hematopoietic stem cell transplantation

Judith A. Wade, Carolyn Katovich Hurley, Steven K. Takemoto, John Thompson, Stella M. Davies, Thomas C. Fuller, Glenn Rodey, Dennis L. Confer, Harriet Noreen, Michael Haagenson, Fangyu Kan, John Klein, Mary Eapen, Stephen Spellman, Craig Kollman

Blood (2007) 109 (9): 4064–4070.

https://doi.org/10.1182/blood-2006-06-032193

Published: 2007

Journal Articles

Impact of Increased Body Weight on Acute Toxicity and Outcome of Autologous Stem Cell Transplantation for Non-Hodgkin’s Lymphoma: A Southwest Oncology Group Analysis.

Patrick Stiff, MD, Joseph Unger, MS, Stephen Forman, MD, Michael LeBlanc, PhD, Thomas Miller, MD, Oliver Press, MD, John Thompson, MD, Richard Fisher, MD

Blood (2004) 104 (11): 352.

https://doi.org/10.1182/blood.V104.11.352.352

Published: 2004

Journal Articles

Mice Transgenic for the Human CGM6 Gene Express Its Product, the Granulocyte Marker CD66b, Exclusively in Granulocytes

Anne-Marie Eades-Perner, John Thompson, Herman van der Putten, Wolfgang Zimmermann

Blood (1998) 91 (2): 663–672.

https://doi.org/10.1182/blood.V91.2.663

Published: 1998

NARROW

Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase I Trial

A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 "Do Not Eat" Signal

Mature Results of a Phase 1-2 Open-Label, Dose-Escalation Study of Intravenous SNS01-T in Patients (pts) with Relapsed or Refractory B-Cell Malignancies

Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of a Novel, First-in-Class Modulator of Eukaryotic Translation Initiation Factor 5A (eIF5A) in Patients (pts) with Relapsed or Refractory B-Cell Malignancies: Data from a Phase 1-2 Study

Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study To Evaluate The Safety and Tolerability Of Intravenous Infusion Of SNS01-T In Patients With Relapsed Or Refractory Multiple Myeloma, Mantle Cell Lymphoma, Or Diffuse Large B Cell Lymphoma

Sensitive and Specific Antibody Probes Directed Against The Erythropoietin Receptor – From Basic Studies To Clinical Implementation

Apixaban Reduces Hospitalization In Patients With Venous Thromboembolism: An Analysis Of The AMPLIFY-EXT Trial

SNS01-T Exhibits Significant Anti-Tumoral Activity In Models Of Multiple Myeloma and Non-Hodgkins B Cell Lymphoma and Induces Cell Death In Malignant But Not Normal B Cells

Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma.

Combination Therapy with Novel Nanoparticle, SNS01-T, and Lenalidomide Triggers Synergistic Cytotoxicity in Vitro and in Vivo in Multiple Myeloma and Mantle Cell Lymphoma

Pharmacodynamic, Biodistribution and Toxicology Results for SNS01-T, a Nanoparticle That Targets eIF5A for the Treatment of Multiple Myeloma

HLA mismatching within or outside of cross-reactive groups (CREGs) is associated with similar outcomes after unrelated hematopoietic stem cell transplantation

Impact of Increased Body Weight on Acute Toxicity and Outcome of Autologous Stem Cell Transplantation for Non-Hodgkin’s Lymphoma: A Southwest Oncology Group Analysis.

Mice Transgenic for the Human CGM6 Gene Express Its Product, the Granulocyte Marker CD66b, Exclusively in Granulocytes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only